February 27, 2023 — 07:02 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Protalix BioTherapeutics Inc. (PLX) reported that its net loss for the year ended December 31, 2022 narrowed to about $14.9 million or $0.31 per share from $27.6 million or $0.62 per share last year.
Total revenues for the year grew to $47.64 million from $38.35 million in the prior year.
Revenue from licenses and R&D services for the year ended December 31, 2022 were $22.3 million, an increase of $0.7 million, or 3% from the prior year. Revenues from license and R&D services represent mainly the revenues the Company recognized in connection with its license and supply agreements with Chiesi.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.